Yahoo
Paris - Delayed Quote EUR

Novacyt S.A. (ALNOV.PA)

0.4300 +0.0200 (+4.88%)
As of 3:15:54 PM GMT+1. Market Open.
Chart Range Bar
Loading chart for ALNOV.PA
  • Previous Close 0.4100
  • Open 0.4130
  • Bid --
  • Ask --
  • Day's Range 0.4125 - 0.4300
  • 52 Week Range 0.2900 - 1.0400
  • Volume 54,082
  • Avg. Volume 269,182
  • Market Cap (intraday) 31.185M
  • Beta (5Y Monthly) 1.37
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3600
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.

www.novacyt.com

228

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

ALNOV.PA
9.97%
CAC 40 (^FCHI)
1.08%

1-Year Return

ALNOV.PA
4.02%
CAC 40 (^FCHI)
3.62%

3-Year Return

ALNOV.PA
32.65%
CAC 40 (^FCHI)
15.80%

5-Year Return

ALNOV.PA
84.47%
CAC 40 (^FCHI)
16.96%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -102.49%

  • Return on Assets (ttm)

    -13.62%

  • Return on Equity (ttm)

    -75.24%

  • Revenue (ttm)

    21.79M

  • Net Income Avi to Common (ttm)

    -22.41M

  • Diluted EPS (ttm)

    -0.3600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.93M

  • Total Debt/Equity (mrq)

    54.74%

  • Levered Free Cash Flow (ttm)

    5.76M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: